Nowakowska J, Radomska D, Czarnomysy R, Marciniec K
Molecules. 2024; 29(15).
PMID: 39124943
PMC: 11314068.
DOI: 10.3390/molecules29153538.
Hooda P, Taxak V, Malik R, Khatri S, Phogat P, Khatkar S
Photochem Photobiol Sci. 2022; 21(11):2011-2034.
PMID: 35932374
DOI: 10.1007/s43630-022-00275-3.
Singh S, Dhanawat M, Gupta S, Kumar D, Kakkar S, Nair A
Curr Neuropharmacol. 2020; 19(2):136-151.
PMID: 33176653
PMC: 8033975.
DOI: 10.2174/1570159X18666201111110136.
Lavorgna M, Iacovino R, Russo C, Di Donato C, Piscitelli C, Isidori M
Int J Mol Sci. 2019; 20(2).
PMID: 30669399
PMC: 6359225.
DOI: 10.3390/ijms20020416.
Gao Y, Chen S
Int J Anal Chem. 2018; 2018:1375215.
PMID: 29955229
PMC: 6000864.
DOI: 10.1155/2018/1375215.
Nanoparticles with high payloads of pipemidic acid, a poorly soluble crystalline drug: drug-initiated polymerization and self-assembly approach.
Pancani E, Menendez-Miranda M, Pastor A, Brisset F, Bernet-Camard M, Desmaele D
Acta Pharm Sin B. 2018; 8(3):420-431.
PMID: 29881681
PMC: 5989915.
DOI: 10.1016/j.apsb.2018.03.008.
Synthesis and in vitro antimicrobial activity screening of new pipemidic acid derivatives.
Popiolek L, Biernasiuk A, Paruch K, Malm A, Wujec M
Arch Pharm Res. 2018; 41(6):633-645.
PMID: 29619676
PMC: 6028826.
DOI: 10.1007/s12272-018-1025-3.
β-Cyclodextrin inclusion complex to improve physicochemical properties of pipemidic acid: characterization and bioactivity evaluation.
Iacovino R, Rapuano F, Caso J, Russo A, Lavorgna M, Russo C
Int J Mol Sci. 2013; 14(7):13022-41.
PMID: 23799358
PMC: 3742172.
DOI: 10.3390/ijms140713022.
High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development.
Junker L, Clardy J
Antimicrob Agents Chemother. 2007; 51(10):3582-90.
PMID: 17664319
PMC: 2043262.
DOI: 10.1128/AAC.00506-07.
In vitro and in vivo activity of DL-8280, a new oxazine derivative.
Sato K, Matsuura Y, Inoue M, Une T, Osada Y, Ogawa H
Antimicrob Agents Chemother. 1982; 22(4):548-53.
PMID: 6960805
PMC: 183791.
DOI: 10.1128/AAC.22.4.548.
Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.
Rella M, Haas D
Antimicrob Agents Chemother. 1982; 22(2):242-9.
PMID: 6821455
PMC: 183719.
DOI: 10.1128/AAC.22.2.242.
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
Nakamura S, Minami A, Katae H, Inoue S, Yamagishi J, Takase Y
Antimicrob Agents Chemother. 1983; 23(5):641-8.
PMID: 6575721
PMC: 184780.
DOI: 10.1128/AAC.23.5.641.
Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.
Klinge E, Mannisto P, Mantyla R, Mattila J, Hanninen U
Antimicrob Agents Chemother. 1984; 26(1):69-73.
PMID: 6476816
PMC: 179919.
DOI: 10.1128/AAC.26.1.69.
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.
Hirai K, Ito A, Abe Y, SUZUE S, IRIKURA T, Inoue M
Antimicrob Agents Chemother. 1981; 19(1):188-9.
PMID: 6454381
PMC: 181380.
DOI: 10.1128/AAC.19.1.188.
New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.
Yamagishi J, Furutani Y, Inoue S, Ohue T, Nakamura S, Shimizu M
J Bacteriol. 1981; 148(2):450-8.
PMID: 6271730
PMC: 216226.
DOI: 10.1128/jb.148.2.450-458.1981.
The in vitro and in vivo activity of ciprofloxacin.
Zeiler H, Grohe K
Eur J Clin Microbiol. 1984; 3(4):339-43.
PMID: 6237902
DOI: 10.1007/BF01977490.
In vitro and in vivo antibacterial activity of AT-2266.
Kouno K, Inoue M, Mitsuhashi S
Antimicrob Agents Chemother. 1983; 24(1):78-84.
PMID: 6226242
PMC: 185107.
DOI: 10.1128/AAC.24.1.78.
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
Nakamura S, Nakata K, Katae H, Minami A, Kashimoto S, Yamagishi J
Antimicrob Agents Chemother. 1983; 23(5):742-9.
PMID: 6223579
PMC: 184805.
DOI: 10.1128/AAC.23.5.742.
Mode of action of a new nalidixic acid derivative, AB206.
Nagate T, Komatsu T, Izawa A, Ohmura S, Namiki S, Mitsuhashi S
Antimicrob Agents Chemother. 1980; 17(5):763-9.
PMID: 6156644
PMC: 283872.
DOI: 10.1128/AAC.17.5.763.
In vitro and in vivo activity of NY-198, a new difluorinated quinolone.
Hirose T, Okezaki E, Kato H, Ito Y, Inoue M, Mitsuhashi S
Antimicrob Agents Chemother. 1987; 31(6):854-9.
PMID: 3476021
PMC: 284199.
DOI: 10.1128/AAC.31.6.854.